TL;DR: Wegovy is MHRA-approved and NICE-recommended for weight management in the UK. On the NHS, it's available through specialist weight management services at £9.90 per prescription in England (free in Scotland, Wales, and Northern Ireland), but waiting lists average 16 months and eligibility criteria are strict: BMI of 35 or above, or 30 or above with a weight-related comorbidity. Most people in the UK access Wegovy through private online prescribers, where it costs £100 to £299 per month depending on dose. In January 2026, the MHRA approved a new 7.2mg dose (triple the previous maximum), making the UK the first country in the world to offer it. Mounjaro (tirzepatide) is also MHRA-approved for weight management and available privately from £120 per month.

Wegovy has been available in the UK since 2023, and it's one of the few countries where the NHS subsidises weight loss medication at all. The catch: getting it through the NHS requires navigating specialist referrals, meeting strict criteria, and waiting over a year in most areas.

The private market has filled the gap. Dozens of online prescribers now offer Wegovy with next-day delivery, and in January 2026 the UK became the first country to approve a higher 7.2mg dose.

This guide covers every pathway to Wegovy in the UK: who qualifies, what it costs, which online services are worth considering, and what's changing in 2026.

What's Approved in the UK

The MHRA (Medicines and Healthcare products Regulatory Agency) has approved several GLP-1 medications for weight management. Each has different licensed indications, pricing, and NHS access status.

| Medication | Active Ingredient | MHRA-Approved For | NHS Access | |---|---|---|---| | Wegovy | Semaglutide (up to 7.2mg) | Chronic weight management | NICE-recommended via specialist services | | Mounjaro | Tirzepatide (up to 15mg) | T2D and chronic weight management | NICE-recommended via specialist services | | Saxenda | Liraglutide (3mg daily) | Chronic weight management | Limited NHS access (largely superseded) | | Ozempic | Semaglutide (up to 1mg) | Type 2 diabetes only | NHS for T2D; off-label weight loss is private | | Orlistat | Orlistat | Weight management | Available on NHS and OTC |

The key distinction: Wegovy and Ozempic contain the same active ingredient (semaglutide), but Wegovy is licensed at higher doses specifically for weight loss. Ozempic is licensed only for type 2 diabetes. Your doctor can prescribe Ozempic off-label for weight loss, but it won't be available through the NHS weight management pathway, and the maximum dose (1mg) is lower than Wegovy's maintenance dose (2.4mg, or the new 7.2mg).

For a full comparison of how these drugs work and differ, see the four main GLP-1 drugs explained.

Getting Wegovy on the NHS

Wegovy is NICE-recommended (Technology Appraisal TA875), which means it should be available on the NHS in England. In practice, access depends on where you live, how long you're willing to wait, and whether you meet a set of layered eligibility criteria.

NICE Eligibility Criteria

To qualify for NHS-funded Wegovy, you must meet all of the following:

BMI of 35 kg/m² or above, OR BMI of 30 to 34.9 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnoea, cardiovascular disease, or similar)
Be referred to and accepted by a Tier 3 or Tier 4 specialist weight management service
Commit to a reduced-calorie diet and increased physical activity alongside the medication
Be part of a structured lifestyle support programme

For people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, BMI thresholds are typically reduced by 2.5 kg/m² (so 32.5 and 27.5 respectively).

What You'll Pay on the NHS

| UK Nation | Prescription Charge | |---|---| | England | £9.90 per prescription | | Scotland | Free | | Wales | Free | | Northern Ireland | Free |

If you're in England and hold an exemption certificate (for diabetes, a pre-payment certificate, or other qualifying conditions), prescriptions may also be free or reduced.

In terms of pure medication cost, NHS Wegovy is remarkably affordable. The barrier is getting to that point.

The Referral Process

Wegovy on the NHS cannot be prescribed by a GP directly. The pathway is:

Speak with your GP. Discuss your weight management history, including any previous diet and exercise programmes. Your GP assesses whether you meet the criteria for referral.
GP refers you to a Tier 3 specialist weight management service. These are multidisciplinary teams typically including dietitians, psychologists, physicians, and exercise specialists.
The specialist service assesses you. They confirm eligibility, review contraindications, and determine which medication is appropriate (Wegovy, Mounjaro, or in some cases Saxenda).
If approved, treatment begins alongside a structured lifestyle programme.

The Waiting List Reality

Here's where theory meets practice. Tier 3 specialist weight management services in England have average waiting times of 16 months. Many areas report waits exceeding 20 months, and some services have waiting lists stretching beyond two years.

Several factors drive this:

Only 76% of Integrated Care Boards (ICBs) commission Tier 3 services at all, meaning roughly a quarter of areas have limited or no local provision
Average new patient capacity is approximately 1,200 per year per ICB, which is far below demand
Local commissioning decisions create a postcode lottery: some areas prioritise BMI of 40 or above with multiple comorbidities, effectively raising the bar above NICE guidance

The practical consequence is that most people who meet NICE criteria still cannot access NHS Wegovy within a reasonable timeframe. This is the primary reason the private market has grown so rapidly.

NICE Stopping Rules

NICE recommends that treatment be reviewed at 6 months. If you've lost less than 5% of your initial body weight, your clinician should consider stopping Wegovy. Maximum treatment duration on the NHS is 2 years, though the guidance notes that continued prescribing beyond this may be appropriate in some cases.

Getting Wegovy Privately

The majority of UK Wegovy users access it through private prescriptions, either from a private GP, a weight management clinic, or (most commonly) an online prescriber.

Who Can Prescribe

Any GMC-registered doctor can write a private prescription for Wegovy. You'll need to meet the licensed indications:

BMI of 30 kg/m² or above (obesity), OR
BMI of 27 kg/m² or above with at least one weight-related comorbidity

Private prescribers don't need to be specialists, and there's no requirement for Tier 3 referral. The consultation and prescribing happen directly.

What You'll Pay

Private Wegovy pricing depends on your dose (which increases through a titration schedule over 16 weeks) and your provider.

Typical monthly costs by dose:

| Dose | Weekly Schedule | Monthly Cost | |---|---|---| | 0.25mg (weeks 1 to 4) | Starter | £100 to £140 | | 0.5mg (weeks 5 to 8) | Titration | £110 to £160 | | 1mg (weeks 9 to 12) | Titration | £130 to £190 | | 1.7mg (weeks 13 to 16) | Titration | £189 to £249 | | 2.4mg (week 17 onward) | Maintenance | £219 to £299 | | 7.2mg (if prescribed) | Higher dose | pricing still stabilising |

Annual costs at the maintenance dose of 2.4mg range from roughly £2,600 to £3,600, depending on provider. Some services include consultations and monitoring in their pricing; others charge these separately (typically £20 to £150 for an initial consultation).

Major Online Prescribers

Several CQC-registered online services offer Wegovy prescriptions with home delivery. Pricing and clinical rigour vary.

Boots Online Doctor: One of the most recognised names. Wegovy costs approximately £199 to £229 per month through their service, which includes a clinical consultation and home delivery. The higher pricing reflects Boots' brand premium and high-street pharmacy infrastructure.

Numan: Offers Wegovy from £139 per month. Includes a weight loss programme with access to nutritionists, exercise physiologists, and behaviour change specialists. Originally launched as a men's health platform, now serves both men and women for weight management.

Juniper: Operated by Eucalyptus Health (the same company behind Australia's largest online weight loss service). Reports that patients lose an average of 23% body weight over one year on their programme. Combines medication with health coaching.

heySlim, SheMed, and others: Smaller online prescribers sometimes offer lower pricing, with Wegovy starting from £75 to £89 per month at the lowest doses. Compare carefully: the cheapest option may lack comprehensive clinical oversight, and prices for maintenance doses tend to converge across providers.

What to Look For in an Online Prescriber

The quality of clinical assessment varies enormously across the UK's online weight loss market. Important markers:

CQC registration. Every legitimate online prescriber must be registered with the Care Quality Commission. Check their registration before ordering.

Clinical consultation. The best services conduct a video or phone consultation (particularly for first-time patients) rather than relying solely on an asynchronous questionnaire. A questionnaire-only model can miss contraindications that a conversation would catch.

Screening for contraindications. Quality providers screen for eating disorders, thyroid conditions, personal or family history of medullary thyroid carcinoma, pancreatitis history, and mental health conditions. If a service doesn't ask about these, that's a red flag.

Ongoing monitoring. Responsible providers schedule regular check-ins (typically monthly or quarterly) to monitor side effects, weight loss progress, and whether dose adjustments are needed.

The New 7.2mg Dose

On January 16, 2026, the MHRA approved a weekly Wegovy dose of 7.2mg for obesity treatment. The UK became the first country in the world to approve this higher dose (the US FDA decision is still pending).

What This Means

The 7.2mg dose is three times the previous maximum of 2.4mg. In the STEP UP clinical trial, participants on 7.2mg achieved approximately 18.7% average body weight loss, with adherent participants losing up to 20.7%. This brings Wegovy's efficacy closer to the results seen with Mounjaro's highest doses.

How It Works (For Now)

The 7.2mg dose is currently administered as three 2.4mg injections on the same day each week. A single-pen 7.2mg device is in development and expected later in 2026.

Who's Eligible

The higher dose is only available to patients who:

Have a BMI of 30 kg/m² or above
Have already been on the 2.4mg dose for at least four weeks
Have tolerated the lower dose without significant issues

It does not apply to patients using Wegovy solely to reduce cardiovascular risk.

NHS vs Private Access

The 7.2mg dose is available immediately through private prescription. NHS access requires a separate NICE review, which has not yet been completed. This means NHS patients are currently limited to the 2.4mg maximum, while private patients can access the higher dose.

Mounjaro: The Main Alternative

Mounjaro (tirzepatide) is the other major MHRA-approved weight loss injection in the UK. It works on two hormone receptors (GIP and GLP-1) compared to Wegovy's single GLP-1 mechanism, and clinical trials showed somewhat greater average weight loss at the highest doses.

Pricing

| Dose | Monthly Cost (Private) | |---|---| | 2.5mg (starter) | £120 to £220 | | 5mg | £140 to £240 | | 7.5mg | £170 to £260 | | 10mg | £190 to £290 | | 15mg (maximum) | £210 to £340 |

Mounjaro is generally priced similarly to Wegovy at equivalent stages of treatment. Both are available through the same online prescribers. For a detailed comparison of efficacy, side effects, and dosing between the two, see the four main GLP-1 drugs explained.

NHS Access for Mounjaro

NICE has also recommended Mounjaro for weight management (TA1026), through the same Tier 3 specialist weight management pathway as Wegovy. The same waiting list issues apply.

In September 2025, Eli Lilly increased Mounjaro's wholesale prices significantly, which some pharmacies passed through to patients. Worth checking current pricing before committing to a subscription.

Other Options

Saxenda (Liraglutide)

Saxenda was the first injectable GLP-1 weight loss drug approved in the UK and is still available, but it's been largely superseded by Wegovy and Mounjaro. It requires daily injections (compared to weekly for Wegovy and Mounjaro) and produces more modest weight loss (roughly 5% to 10% average body weight versus 15% to 20%+ for the newer drugs).

Private pricing: approximately £177 to £288 per month. NHS access is limited through specialist services.

Off-Label Ozempic

Some private doctors prescribe Ozempic off-label for weight management. The maximum dose is 1mg weekly (versus Wegovy's 2.4mg or 7.2mg), so the weight loss effect is lower. Private pricing for Ozempic is roughly £150 to £250 per month. This can make sense if Wegovy is unavailable or if lower-dose semaglutide is clinically appropriate.

Orlistat

The only weight loss medication available both on NHS prescription and over the counter (as Alli). It works by blocking fat absorption in the gut rather than through appetite suppression. Significantly less effective than GLP-1 drugs (roughly 3% to 5% additional weight loss versus placebo), but also significantly cheaper at approximately £20 to £50 per month.

Compounding and Research Peptides: The Legal Position

In the UK, semaglutide is classified as a prescription-only medicine. The MHRA regulates it under the Human Medicines Regulations 2012.

Compounding pharmacies in the UK cannot legally manufacture and sell injectable semaglutide products in the way that was common in the United States during the shortage period. Any semaglutide product sold in the UK must either be a licensed product (Wegovy, Ozempic) or dispensed by a registered pharmacy under a valid prescription.

"Research peptide" sellers sometimes market semaglutide labelled "for research purposes only." Buying these products for self-injection is both medically risky and legally questionable. The MHRA has taken enforcement action against companies selling unlicensed medicines marketed as peptides, and products purchased from unregulated sources carry real risks of contamination, incorrect dosing, and absence of active ingredient entirely.

Private Health Insurance

Unlike the NHS, most UK private health insurers (BUPA, AXA Health, Aviva, Vitality) do not routinely cover Wegovy or other weight loss medications as part of standard policies. Some insurers offer partial coverage through specific wellness or chronic disease management programmes, but this is the exception rather than the norm.

If you have private medical insurance and want to check coverage, contact your provider directly. A small number of employer-sponsored plans have begun including weight management medication as a benefit, particularly where the employer can demonstrate long-term cost savings through reduced sickness absence and health claims.

What's Coming Next

Oral semaglutide for weight management. An oral formulation is in late-stage development. If approved by the MHRA, it would eliminate the injection barrier that deters some patients. Rybelsus (oral semaglutide at lower doses for type 2 diabetes) is already available in the UK.

Orforglipron (Eli Lilly). An oral GLP-1 receptor agonist showing strong weight loss results in clinical trials. Eli Lilly has indicated potential availability as early as Q2 2026, though UK approval timelines may lag the US.

Expanded NHS capacity. NHS England published an enhanced weight management service specification for 2025 to 2026, signalling intent to expand Tier 2 and Tier 3 services. Whether this translates to meaningfully shorter waiting times remains to be seen.

Generic semaglutide (international). Semaglutide patents have already expired in India and Canada, where generics are launching at 50% to 90% lower prices. UK patent protection extends further, but international generic availability may eventually influence pricing. For context on what generic competition looks like, see generic semaglutide in India and generic semaglutide in Canada.

A Practical Decision Tree

Can you wait 12 to 20+ months? Ask your GP for a referral to your local Tier 3 specialist weight management service. If you meet NICE criteria (BMI 35+, or 30+ with comorbidities), you may eventually access Wegovy or Mounjaro at £9.90 per prescription (or free outside England).

Can you afford £100 to £300 per month? A private online prescriber is the fastest route. You can typically start treatment within a week of your initial consultation. Compare pricing across providers at your expected maintenance dose (not just the starter price), and prioritise services with proper clinical oversight.

Is the cost prohibitive? Orlistat is available on the NHS from your GP and over the counter as Alli, at a fraction of the cost. Less effective than GLP-1 drugs, but accessible immediately. Your GP can also discuss non-pharmaceutical approaches.

Considering alternatives to medication? Weight loss medication works best as part of a broader strategy that addresses the behavioural and psychological dimensions of eating. For an evidence-based perspective on why willpower-based approaches so often fail, and what the research says about more sustainable alternatives, see why diets fail at the psychological level.

For a detailed breakdown of what Wegovy costs across all pathways, including annual projections and money-saving strategies, see Wegovy cost in the UK.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication, including semaglutide. Pricing, NHS eligibility, and drug availability are subject to change. For the latest NICE guidance, visit nice.org.uk.

Ready to stop fighting your cravings and start reprogramming your mind for lasting success? The Hypna AI 21-day self-hypnosis program is designed to help you rewire subconscious patterns and build a healthier relationship with food from the inside out.

📲 Download Hypna AI to start your journey tonight.